Functioning in patients with major depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia
- Authors
- Novick, Diego; Montgomery, William; Haro, Josep Maria; Moneta, Maria Victoria; Zhu, Gang; Yue, Li; Hong, Jihyung; Duenas, Hector; Brugnoli, Roberto
- Issue Date
- 2016
- Publisher
- DOVE MEDICAL PRESS LTD
- Keywords
- depression; antidepressant; duloxetine; SSRI; functioning
- Citation
- NEUROPSYCHIATRIC DISEASE AND TREATMENT, v.12, pp.383 - 392
- Journal Title
- NEUROPSYCHIATRIC DISEASE AND TREATMENT
- Volume
- 12
- Start Page
- 383
- End Page
- 392
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/9698
- DOI
- 10.2147/NDT.S100675
- ISSN
- 1178-2021
- Abstract
- Purpose: To assess and compare the levels of functioning in patients with major depressive disorder treated with either duloxetine with a daily dose of <= 60 mg or a selective serotonin reuptake inhibitor (SSRI) as monotherapy for up to 6 months in a naturalistic setting in East Asia. In addition, this study examined the impact of painful physical symptoms (PPS) on the effects of these treatments. Patients and methods: Data for this post hoc analysis were taken from a 6-month prospective observational study involving 1,549 patients with major depressive disorder without sexual dysfunction. The present analysis focused on a subgroup of patients from East Asia (n= 587). Functioning was measured using the Sheehan Disability Scale (SDS). Depression severity was assessed using the 16-item Quick Inventory of Depressive Symptomatology-Self Report. PPS were rated using the modified Somatic Symptom Inventory. A mixed model with repeated measures was fitted to compare the levels of functioning between duloxetine-treated (n= 227) and SSRI-treated (n= 225) patients, adjusting for baseline patient characteristics. Results: The mean SDS total score was similar between the two treatment cohorts (15.46 [standard deviation = 6.11] in the duloxetine cohort and 16.36 [standard deviation = 6.53] in the SSRI cohort, P= 0.077) at baseline. Both descriptive and regression analyses confirmed improvement in functioning in both groups during follow-up, but duloxetine-treated patients achieved better functioning. At 24 weeks, the estimated mean SDS total score was 4.48 (standard error = 0.80) in the duloxetine cohort, which was statistically significantly lower (ie, better functioning) than that of 6.76 (standard error = 0.77) in the SSRI cohort (P< 0.001). This treatment difference was more apparent in the subgroup of patients with PPS at baseline. Similar patterns were also observed for SDS subscores (work, social life, and family life). Conclusion: Depressed patients treated with duloxetine achieved better functioning compared to those treated with SSRIs. This treatment difference was mostly driven by patients with PPS at baseline.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 사회과학대학 > 의료경영학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/9698)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.